Countering TRAIL Resistance in Melanoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 May 15

PMID 31083589

Citations 26

Authors

Jurgen Eberle

Affiliations

Soon will be listed here.

Abstract

Melanoma of the skin has become a prime example for demonstrating the success of targeted cancer therapy. Nevertheless, high mortality has remained, mainly related to tumor heterogeneity and inducible therapy resistance. But the development of new therapeutic strategies and combinations has raised hope of finally defeating this deadly disease. TNF-related apoptosis-inducing ligand (TRAIL) represents a promising antitumor strategy. The principal sensitivity of melanoma cells for TRAIL was demonstrated in previous studies; however, inducible resistance appeared as a major problem. To address this issue, combination strategies were tested, and survival pathway inhibitors were shown to sensitize melanoma cells for TRAIL-induced apoptosis. Finally, cell cycle inhibition was identified as a common principle of TRAIL sensitization in melanoma cells. Mitochondrial apoptosis pathways, pro- and antiapoptotic Bcl-2 proteins as well as the rheostat consisted of Smac (Second mitochondria-derived activator of caspase) and XIAP (X-linked inhibitor of apoptosis protein) appeared to be of particular importance. Furthermore, the role of reactive oxygen species (ROS) was recognized in this setting. Inducible TRAIL resistance in melanoma can be explained by (i) high levels of antiapoptotic Bcl-2 proteins, (ii) high levels of XIAP, and (iii) suppressed Bax activity. These hurdles have to be overcome to enable the use of TRAIL in melanoma therapy. Several strategies appear as particularly promising, including new TRAIL receptor agonists, Smac and BH3 mimetics, as well as selective kinase inhibitors.

Citing Articles

Enhanced Anti-Melanoma Activity of Nutlin-3a Delivered via Ethosomes: Targeting p53-Mediated Apoptosis in HT144 Cells.

Romani A, Lodi G, Casciano F, Gonelli A, Secchiero P, Zauli G Cells. 2024; 13(20.

PMID: 39451196 PMC: 11506859. DOI: 10.3390/cells13201678.

Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x/Bcl-w Inhibitors.

Peng Z, Gillissen B, Richter A, Sinnberg T, Schlaak M, Eberle J Int J Mol Sci. 2024; 25(6).

PMID: 38542429 PMC: 10970841. DOI: 10.3390/ijms25063453.

Antihepatoma peptide, scolopentide, derived from the centipede scolopendra subspinipes mutilans.

Hu Y, Liu Z, Zhang Z, Deng Z, Huang Z, Feng T World J Gastroenterol. 2023; 29(12):1875-1898.

PMID: 37032730 PMC: 10080696. DOI: 10.3748/wjg.v29.i12.1875.

Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins.

Peng Z, Gillissen B, Richter A, Sinnberg T, Schlaak M, Eberle J Int J Mol Sci. 2023; 24(5).

PMID: 36902392 PMC: 10002974. DOI: 10.3390/ijms24054961.

Tobacco nicotine promotes TRAIL resistance in lung cancer through SNHG5.

Xiao X, Xu J, Sheng X, Wang C, Dong J, Shi X Exp Ther Med. 2023; 25(3):131.

PMID: 36845946 PMC: 9947578. DOI: 10.3892/etm.2023.11830.

References

Raisova M, Hossini A, Eberle J, Riebeling C, Wieder T, Sturm I . The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol. 2001; 117(2):333-40. DOI: 10.1046/j.0022-202x.2001.01409.x. View

Zhang X, Zhang X, Gray C, Nguyen T, Hersey P . Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res. 2001; 61(19):7339-48. View

Johnstone R, Ruefli A, Lowe S . Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108(2):153-64. DOI: 10.1016/s0092-8674(02)00625-6. View

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

Ashkenazi A . Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2(6):420-30. DOI: 10.1038/nrc821. View

Fischer U, Janicke R, Schulze-Osthoff K . Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ. 2003; 10(1):76-100. PMC: 7091709. DOI: 10.1038/sj.cdd.4401160. View

Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C . Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003; 10(3):356-64. DOI: 10.1038/sj.cdd.4401157. View

Zhang X, Borrow J, Zhang X, Nguyen T, Hersey P . Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene. 2003; 22(19):2869-81. DOI: 10.1038/sj.onc.1206427. View

Chawla-Sarkar M, Bae S, Reu F, Jacobs B, Lindner D, Borden E . Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2004; 11(8):915-23. DOI: 10.1038/sj.cdd.4401416. View

10.

Nachmias B, Ashhab Y, Ben-Yehuda D . The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol. 2004; 14(4):231-43. DOI: 10.1016/j.semcancer.2004.04.002. View

11.

Kelley S, Ashkenazi A . Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol. 2004; 4(4):333-9. DOI: 10.1016/j.coph.2004.02.006. View

12.

Von Haefen C, Gillissen B, Hemmati P, Wendt J, Guner D, Mrozek A . Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene. 2004; 23(50):8320-32. DOI: 10.1038/sj.onc.1207971. View

13.

Zhang L, Fang B . Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2004; 12(3):228-37. DOI: 10.1038/sj.cgt.7700792. View

14.

Gillespie S, Zhang X, Hersey P . Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther. 2005; 3(12):1651-8. View

15.

van Geelen C, de Vries E, de Jong S . Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat. 2005; 7(6):345-58. DOI: 10.1016/j.drup.2004.11.002. View

16.

Willis S, Adams J . Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol. 2005; 17(6):617-25. PMC: 2930980. DOI: 10.1016/j.ceb.2005.10.001. View

17.

Kurbanov B, Geilen C, Fecker L, Orfanos C, Eberle J . Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol. 2005; 125(5):1010-9. DOI: 10.1111/j.0022-202X.2005.23900.x. View

18.

van Delft M, Huang D . How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res. 2006; 16(2):203-13. DOI: 10.1038/sj.cr.7310028. View

19.

Zhang X, Wu J, Gillespie S, Borrow J, Hersey P . Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clin Cancer Res. 2006; 12(4):1355-64. DOI: 10.1158/1078-0432.CCR-05-2084. View

20.

Kim B, Ryu S, Song B . JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem. 2006; 281(30):21256-21265. DOI: 10.1074/jbc.M510644200. View